Baseline mean deviation and rates of visual field change in treated glaucoma patients

Eye

Volumn 25, Issue 5, 2011, Pages 626-632

  Forchheimer, I ^a   De Moraes, C G ^a,b   Teng, C C ^a,b,c   Folgar, F ^a   Tello, C ^b,c   Ritch, R ^b,c   Liebmann, J M ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

glaucoma; mean deviation; progression; visual field

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FILTERING OPERATION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPTIC NERVE DISEASE; VISUAL FIELD; VISUAL FIELD DEFECT;

EID: 79955998953     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.33     Document Type: Article

References (27)

1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713. (Pubitemid 34620348)
2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279. (Pubitemid 36105431)
3. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 490-491.
4. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA et al. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-1953. (Pubitemid 33032760)
5. Miglior S, Torri V, Zeyen T, Pfeiffer N, Vaz JC, Adamsons I. Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol 2007; 144(2): 266-275.
6. Medeiros FA, Sample PA, Zangwill LM, Bowd C, Aihara M, Weinreb RN. Corneal thickness as a risk factor for visual field loss in patients with preperimetric glaucomatous optic neuropathy. Am J Ophthalmol 2003; 136: 805-813. (Pubitemid 37330022)
7. Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001; 131: 699-708. (Pubitemid 32522638)
8. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114: 1965-1972. (Pubitemid 350016362)
9. Nouri-Mahdavi K, Hoffman D, Gaasterland D, Caprioli J. Prediction of visual field progression in glaucoma. Invest Ophthalmol Vis Sci 2004; 45: 4346-4351. (Pubitemid 39564659)
10. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714-720. (Pubitemid 34620349)
11. Cioffi GA, Liebmann JM. Translating the OHTS results into clinical practice. J Glaucoma 2002; 11: 375-377.
12. Singh K. The randomized clinical trial: beware of limitations. J Glaucoma 2004; 13: 87-89. (Pubitemid 38372816)
13. Jampel HD. We should treat fewer patients with elevated intraocular pressure now that we know the results of theOcular Hypertension Treatment Study. Arch Ophthalmol 2004; 122: 378-379. (Pubitemid 38314203)
14. Wishart PK. Interpretation of the glaucoma 'landmark studies'. Br J Ophthalmol 2009; 93: 561-562.
15. Kass MA, Gordon MO, Kymes SM. Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Arch Ophthalmol 2005; 123: 1021-1022. (Pubitemid 41058012)
16. Kent DM, Kitsios G. Against pragmatism: on efficacy, effectiveness and the real world. Trials 2009; 10: 48.
17. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-1632. (Pubitemid 37430387)
18. Glasgow RE, Magid DJ, Beck A, Ritzwoller D, Estabrooks PA. Practical clinical trials for translating research to practice: design and measurement recommendations. Med Care 2005; 43: 551-557. (Pubitemid 40847291)
19. De Moraes CG, Ritch R, Liebmann JM. Bridging the major prospective National Eye Institute-sponsored glaucoma clinical trials and clinical practice. J Glaucoma 2011; 20: 1-2.
20. Chauhan BC, Garway-Heath DF, Goñ i FJ, Rossetti L, Bengtsson B, Viswanathan AC et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 2008; 92(4): 569-573. (Pubitemid 351497993)
21. Spry PG, Bates AB, Johnson CA, Chauhan BC. Simulation of longitudinal threshold visual field data. Invest Ophthalmol Vis Sci 2000; 41(8): 2192-2200.
22. De Moraes CG, Juthani V, Liebmann JM, Teng CC, Tello C, Susanna R et al. Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol 2010 (in press).
23. Fitzke FW, Hitchings RA, Poinoosawmy D, McNaught AI, Crabb DP. Analysis of visual field progression in glaucoma. Br J Ophthalmol 1996; 80: 40-48. (Pubitemid 26017558)
24. Gardiner SK, Crabb DP. Examination of different pointwise linear regression methods for determining visual field progression. Invest Ophthalmol Vis Sci 2002; 43: 1400-1407. (Pubitemid 34462637)
25. McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP, Los Angeles Latino Eye Study Group. Severity of visual field loss and health-related quality of life. Am J Ophthalmol 2007; 143: 1013-1023. (Pubitemid 46764652)
26. De Moraes CG, Prata TS, Tello C, Ritch R, Liebmann JM. Glaucoma with early visual field loss affecting both hemifields and the risk of disease progression. Arch Ophthalmol 2009; 127: 1129-1134.
27. Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 1989; 107: 453-464.